

TARO PHARMACEUTICAL INDUSTRIES LTD

Form 6-K

August 05, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2013

Commission File Number 001-35463

Taro Pharmaceutical Industries Ltd.

(Translation of registrant's name into English)

14 Hakitor Street, Haifa Bay 26110, Israel  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby  
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of  
1934. Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  
82-\_\_\_\_\_.

Taro Pharmaceutical Industries  
Ltd.  
c/o Taro Pharmaceuticals U.S.A.,  
Inc.  
Three Skyline Drive  
Hawthorne, New York 10532  
(NYSE: TARO)

CONTACT:

William J. Coote  
VP, Treasurer  
(914) 345-9001  
William.Coote@taro.com

FOR IMMEDIATE RELEASE

Taro to Announce Results for Quarter Ended June 30, 2013

Hawthorne, NY, August 5, 2013– Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today that it plans to release its financial results for the quarter ended June 30, 2013 after market close on Wednesday, August 7, 2013.

Additionally, the release will be accessible on Taro’s website at [www.taro.com](http://www.taro.com).

\*\*\*\*

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit Taro’s website at [www.taro.com](http://www.taro.com).

###

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 5, 2013

TARO PHARMACEUTICAL INDUSTRIES LTD.

By: /s/ Kal Sundaram

Name:

Kal Sundaram

Title:

Chief Executive Officer and Director